Advanced Liver Cancer Clinical Trial
Official title:
Clinical Study Using Precision Cell Immunotherapy Combined With Transcatheter Arterial Chemoembolization in Advanced Liver Cancer
Objectives:
To evaluate the safety and effectiveness of cell therapy using Precision Cells Combined With
TACE in Advanced Liver Cancer.
Eligibility:
Individuals greater than or equal to 18 years of age and less than or equal to 65 years of
age who have been diagnosed with Advanced Liver Cancer.
A total of 40 patients may be enrolled over a period of 1-2 years. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01754987 -
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
|
Phase 1/Phase 2 | |
Recruiting |
NCT05698459 -
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients With Advanced Liver Cancer
|
Phase 1 | |
Recruiting |
NCT03146637 -
Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer
|
Phase 2 | |
Withdrawn |
NCT03484962 -
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer
|
Phase 2 | |
Recruiting |
NCT05603039 -
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04906434 -
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
|
Phase 1 | |
Recruiting |
NCT04163237 -
Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer
|
Phase 3 | |
Recruiting |
NCT02873442 -
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03474822 -
Plasmodium Immunotherapy for Breast and Liver Cancers
|
Phase 1/Phase 2 |